Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The apolipoprotein E type 4 allele ( APOE -ε4) is genetically associated with the common late onset familial and sporadic forms of Alzheimer's disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE -ε4 alleles in 42 families with late onset AD. Thus APOE -ε4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE -ε4 was virtually sufficient to cause AD by age 80.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Common variants of the apolipoprotein E gene (APOE) influence the risk of Alzheimer’s disease: APOE4 is linked to high risk, APOE3 is considered to confer a neutral risk, and APOE2 is associated with relative protection.2–5”
From APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“Compared to the most common APOE3/3 genotype, each additional copy of the APOE4 allele is associated with a higher risk of Alzheimer’s dementia and a younger mean age at dementia onset, such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
91 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Self-citationAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationMiller, R. G. (1981) · Cited by 3,336
Regression analysis of multivariate incomplete failure time data by modeling marginal distributions
Wei, L. J., Lin, D. Y., & Weissfeld, L. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478873 · Cited by 1,868
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Self-citationThe Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D., Drachman, D., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,163
Self-citationNamba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., & Ikeda, K. (1991) · Brain Research · doi:10.1016/0006-8993(91)91092-f · Cited by 1,157
Genetic Linkage Evidence for a Familial Alzheimer's Disease Locus on Chromosome 14
Schellenberg, G. D., Bird, T. D., Wijsman, E. M., Orr, H. T., Anderson, L., Nemens, E., White, J. A., Bonnycastle, L., Weber, J. L., Alonso, M. E., et al. (1992) · Science · doi:10.1126/science.1411576 · Cited by 946
Research works printed but not linked: 3
- SAS/STAT User's Guide Release 6.03 Edition (1988).
- SAS User's Guide: Statistics Version 5 Edition (1985).
- 10.1073/pnas.90.5.1977 · DOI · Paper page
Cited by
Items 1,401–1,500 of 1,689
Mann, K. M. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh199 · Cited by 48
“Alzheimer’s disease (LOAD) ( 5 , 6). Furthermore, the presence of one or more e4 alleles”
BackgroundApolipoprotein E4 has extensive conformational heterogeneity in lipid-free and lipid-bound forms
Stuchell-Brereton, M. D., Zimmerman, M. I., Miller, J. J., Mallimadugula, U. L., Incicco, J. J., Roy, D., Smith, L. G., Cubuk, J., Baban, B., DeKoster, G. T., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2215371120 · Cited by 48
Tate, B. A., & Mathews, P. M. (2006) · Science of Aging Knowledge Environment · doi:10.1126/sageke.2006.10.re2 · Cited by 48
PKR, the double stranded RNA‐dependent protein kinase as a critical target in Alzheimer's disease
Morel, M., Couturier, J., Lafay‐Chebassier, C., Paccalin, M., & Page, G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00849.x · Cited by 47
Beta-amyloid auto-antibodies are reduced in Alzheimer's disease
Qu, B.-X., Gong, Y., Moore, C., Fu, M., German, D. C., Chang, L.-Y., Rosenberg, R., & Diaz-Arrastia, R. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.06.017 · Cited by 47
Evidence that PICALM affects age at onset of Alzheimer's dementia in Down syndrome
Jones, E. L., Mok, K., Hanney, M., Harold, D., Sims, R., Williams, J., & Ballard, C. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.03.018 · Cited by 47
“We tested whether genes that increase the risk of late-onset Alzheimer’s disease influence the age at onset in Down syndrome using genome-wide association data for age at onset of dementia in a small sample of individuals (N ¼ 67) with Down syndrome.”
Magnetic resonance and PET studies in the early diagnosis of Alzheimer’s disease
Mosconi, L., De Santi, S., Rusinek, H., Convit, A., & de Leon, M. J. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.5.831 · Cited by 46
HtrA1 Proteolysis of ApoE In Vitro Is Allele Selective
Chu, Q., Diedrich, J. K., Vaughan, J. M., Donaldson, C. J., Nunn, M. F., Lee, K.-F., & Saghatelian, A. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b03463 · Cited by 46
Lipoprotein glomerulopathy: renal lipidosis induced by novel apolipoprotein E variants
Saito, T., Oikawa, S., Sato, H., & Sasaki, J. (1999) · Nephron · doi:10.1159/000045511 · Cited by 46
“However, the heterozygosity of apo E variants, e.g. apo E2/3 or apo E2/4, found in the majority of LPG cases may prevent the disability for receptor binding. On the other hand, lipoproteins containing aberrant conformational changes in apo E variants may tend to form aggregated deposits. In fact, since the plasma conc…”
BackgroundHuman tau mutations in cerebral organoids induce a progressive dyshomeostasis of cholesterol
Glasauer, S. M. K., Goderie, S. K., Rauch, J. N., Guzman, E., Audouard, M., Bertucci, T., Joy, S., Rommelfanger, E., Luna, G., Keane-Rivera, E., et al. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.07.011 · Cited by 46
Association of APOE with age at onset of sporadic amyotrophic lateral sclerosis
Zetterberg, H., Jacobsson, J., Rosengren, L., Blennow, K., & Andersen, P. M. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.06.025 · Cited by 46
“Moreover, much of the association of APOE ε4 with sporadic, but not necessarily familial, AD is caused by the earlier age at onset in ε4 carriers [23–25].”
BackgroundGao, X. R., Chiariglione, M., Qin, K., Nuytemans, K., Scharre, D. W., Li, Y.-J., & Martin, E. R. (2023) · Scientific Reports · doi:10.1038/s41598-023-27551-1 · Cited by 45
Ayton, S., & Bush, A. I. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101212 · Cited by 45
Li, L., Cao, D., Desmond, R., Rahman, A., Lah, J. J., Levey, A. I., & Zamrini, E. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000164271 · Cited by 45
“All of these mutations cause increased production of highly amyloidogenic Aβ peptides that are deposited in the senile plaques.Increasing evidence suggests that cardiovascular risk factors may play important roles in the development of AD. The apolipoprotein (apo) E4 allele, associated with hypercholesterolemia and co…”
BackgroundAllelic expression of APOE in human brain: Effects of epsilon status and promoter haplotypes
Bray, N. J., Jehu, L., Moskvina, V., Buxbaum, J. D., Dracheva, S., Haroutunian, V., Williams, J., Buckland, P. R., Owen, M. J., & O'Donovan, M. C. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh299 · Cited by 45
“Possession of the 14 allele of the APOE gene (encoding ApoE4) is the only undisputed genetic risk factor for the common, late-onset, form of Alzheimer’s disease (LOAD), increasing risk in a dose-dependent manner (5,6).”
BackgroundHomocysteine and related genetic polymorphisms in down’s syndrome IQ.
Gueant, J.-L. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.039875 · Cited by 45
Genetic Study of Neurexin and Neuroligin Genes in Alzheimer's Disease
Martinez-Mir, A., Initiative, A. D. N., González-Pérez, A., Gayán, J., Antúnez, C., Marín, J., Boada, M., Lopez-Arrieta, J. M., Fernández, E., Ramírez-Lorca, R., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122257 · Cited by 45
“near the APOE transcript is almost universally associated with non-Mendelian AD [1].”
Emergence of a seizure phenotype in aged apolipoprotein epsilon 4 targeted replacement mice
Hunter, J. M., Cirrito, J. R., Restivo, J. L., Kinley, R. D., Sullivan, P. M., Holtzman, D. M., Koger, D., Delong, C., Lin, S., Zhao, L., et al. (2012) · Brain Research · doi:10.1016/j.brainres.2012.05.048 · Cited by 45
Genetic risk factors for Alzheimer disease: emerging roles of microglia in disease pathomechanisms
Takatori, S., Wang, W., Iguchi, A., & Tomita, T. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-05542-4_5 · Cited by 44
Associations between white matter lesions, cerebrovascular risk factors, and low CSF Aβ42
Stenset, V., Johnsen, L., Kocot, D., Negaard, A., Skinningsrud, A., Gulbrandsen, P., Wallin, A., & Fladby, T. (2006) · Neurology · doi:10.1212/01.wnl.0000234030.77831.5a · Cited by 44
“CSF A 42 levels were measured using standardized ELISA (Innotest -Amyloid (1-42), Innogenetics, Belgium).”
MethodTong, L. M., Yoon, S. Y., Andrews-Zwilling, Y., Yang, A., Lin, V., Lei, H., & Huang, Y. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.3815-15.2016 · Cited by 43
“Apolipoprotein (apo) E4 is the strongest genetic risk factor for Alzheimer’s disease (AD)—the fastest-growing neurodegenerative disease facing mankind (Corder et al., 1993; Farrer et al., 1997; Genin et al., 2011; Huang and Mucke, 2012).”
BackgroundCholesterol Dysmetabolism in Alzheimer’s Disease: A Starring Role for Astrocytes?
Staurenghi, E., Giannelli, S., Testa, G., Sottero, B., Leonarduzzi, G., & Gamba, P. (2021) · Antioxidants · doi:10.3390/antiox10121890 · Cited by 44
“Three ApoE isoforms are present in humans (ApoE2, ApoE3, and ApoE4) and AD frequency in ε4 homozygotes is much higher (91%) compared to ε3 homozygotes (20%) [6].”
BackgroundInfluentialHabes, M., Toledo, J. B., Resnick, S. M., Doshi, J., Van der Auwera, S., Erus, G., Janowitz, D., Hegenscheid, K., Homuth, G., Völzke, H., et al. (2016) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4805 · Cited by 44
“The presence of the apolipoprotein E gene (APOE) 4 allele is the strongest genetic sporadic Alzheimer disease (AD) risk factor.(1,2) The APOE gene has 2 additional codominant alleles (APOE 2 and 3).”
BackgroundMechanistic complexities of bone loss in Alzheimer’s disease: a review
Frame, G., Bretland, K. A., & Dengler-Crish, C. M. (2020) · Connective Tissue Research · doi:10.1080/03008207.2019.1624734 · Cited by 44
A multi‐hit hypothesis for an APOE4 ‐dependent pathophysiological state
Steele, O. G., Stuart, A. C., Minkley, L., Shaw, K., Bonnar, O., Anderle, S., Penn, A. C., Rusted, J., Serpell, L., Hall, C., et al. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15685 · Cited by 44
“APOE4 increases LOAD risk by 2 to 8 times for heterozygotic and homozygotic carriers, relative to APOE3-carriers, respectively (Corder et al., 1993, 1994; Gureje et al., 2006; Mayeux et al., 1998; Raber et al., 2004; Saunders et al., 1993).”
BackgroundOng, Q.-R., Chan, E. S., Lim, M.-L., Cole, G. M., & Wong, B.-S. (2014) · Scientific Reports · doi:10.1038/srep03754 · Cited by 44
“Ma, T. et al. Glucagon-Like Peptide-1 Cleavage Product GLP-1(9-36) Amide Rescues Synaptic Plasticity and Memory Deficits in Alzheimer’s Disease Model Mice.”
BackgroundPolvikoski, T., Sulkava, R., Rastas, S., Sutela, A., Niinistö, L., Notkola, I.-L., Verkkoniemi, A., Viramo, P., Juva, K., & Haltia, M. (2006) · Neuroepidemiology · doi:10.1159/000090252 · Cited by 43
“These mild changes eventually expand and lead to clinical AD earlier in the APOE υ4 carriers than in noncarriers [”
BackgroundMicroRNAs in Extracellular Vesicles of Alzheimer’s Disease
Li, W., & Zheng, Y. (2023) · Cells · doi:10.3390/cells12101378 · Cited by 43
“According to ROC analysis, miR-451a has the best performance in distinguishing EOAD or LOAD from HC (AUC = 0.95 and 0.85, respectively, as listed in Table 5) [36].”
BackgroundInfluentialAPOEε4 potentiates amyloid β effects on longitudinal tau pathology
Ferrari-Souza, J. P., Bellaver, B., Ferreira, P. C. L., Benedet, A. L., Povala, G., Lussier, F. Z., Leffa, D. T., Therriault, J., Tissot, C., Soares, C., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00490-2 · Cited by 43
ApoE-isoform-dependent cellular uptake of amyloid-β is mediated by lipoprotein receptor LR11/SorLA
Yajima, R., Tokutake, T., Koyama, A., Kasuga, K., Tezuka, T., Nishizawa, M., & Ikeuchi, T. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.11.111 · Cited by 43
Mahley, R. W. (2023) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2023.102684 · Cited by 43
Implications of apolipoprotein E genotype on inflammation and vitamin E status
Huebbe, P., Lodge, J. K., & Rimbach, G. (2010) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200900398 · Cited by 43
“2 0 0 0 [3 1 ]”
BackgroundVuletic, S., Peskind, E. R., Marcovina, S. M., Quinn, J. F., Cheung, M. C., Kennedy, H., Kaye, J. A., Jin, L., & Albers, J. J. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20458 · Cited by 43
“Previously published studies showed that apoEe4 is more prevalent in patients with AD, suggesting that apoE contributes to the AD risk, age of onset, and the severity of the neuropathology (Corder et al., 1993; Marz et al., 1996; Khachaturian et al., 2004).”
BackgroundHippocampal synaptic and neural network deficits in young mice carrying the humanAPOE 4 gene
Sun, G., He, Y., Ma, X. K., Li, S., Chen, D., Gao, M., Qiu, S., Yin, J., Shi, J., & Wu, J. (2017) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12720 · Cited by 42
Olarte, L., Schupf, N., Lee, J. H., Tang, M.-X., Santana, V., Williamson, J., Maramreddy, P., Tycko, B., & Mayeux, R. (2006) · Archives of Neurology · doi:10.1001/archneur.63.11.1586 · Cited by 42
“Once dementia status was determined by consensus, as described previously, patients with at least 1 first-degree relative with dementia were classified as having FAD and those without a family history of dementia were classified as having SAD.”
ResultInfluentialOrth, M., Weng, W., Funke, H., Steinmetz, A., Assmann, G., Nauck, M., Dierkes, J., Ambrosch, A., Weisgraber, K. H., Mahley, R. W., et al. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.5.1306 · Cited by 42
Abisambra, J. F., Fiorelli, T., Padmanabhan, J., Neame, P., Wefes, I., & Potter, H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008556 · Cited by 42
“About 60–80% of AD patients have at least one copy of apoE4 [2,4,5] and the risk for AD is increased in an e-4 allele dose-dependent manner [6].”
BackgroundImpact of ApoB-100 expression on cognition and brain pathology in wild-type and hAPPsl mice
Löffler, T., Flunkert, S., Havas, D., Sántha, M., Hutter-Paier, B., Steyrer, E., & Windisch, M. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.04.008 · Cited by 42
“Notably, AD, atherosclerosis, and especially coronary artery disease (CAD) share many risk factors, such as diabetes, hypertension, hyperlipidemia, and the inheritance of an apolipoprotein E4 (ApoE4) allele (Corder et al., 1993; Jarvik et al., 1995; Skoog et al., 1999).”
BackgroundMorgan, A. R., Turic, D., Jehu, L., Hamilton, G., Hollingworth, P., Moskvina, V., Jones, L., Lovestone, S., Brayne, C., Rubinsztein, D. C., et al. (2007) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30509 · Cited by 42
“The E4 allele of apolipoprotein E (ApoE) is the only well-established genetic risk factor to increase the likelihood of developing LOAD to date [Corder et al., 1993; Farrer et al., 1997].”
BackgroundHenry, N., Krammer, E.-M., Stengel, F., Adams, Q., Van Liefferinge, F., Hubin, E., Chaves, R., Efremov, R., Aebersold, R., Vandenbussche, G., et al. (2018) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006165 · Cited by 42
HOFFMANN, M. M., SCHARNAGL, H., PANAGIOTOU, E., BANGHARD, W. T., WIELAND, H., & MA[Combining Diaeresis]RZ, W. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v123524 · Cited by 42
Tsuang, D., Larson, E. B., Bowen, J., McCormick, W., Teri, L., Nochlin, D., Leverenz, J. B., Peskind, E. R., Lim, A., Raskind, M. A., et al. (1999) · Archives of Neurology · doi:10.1001/archneur.56.12.1489 · Cited by 42
Unified theory of Alzheimer’s disease (UTAD): implications for prevention and curative therapy
Nehls, M. (2016) · Journal of Molecular Psychiatry · doi:10.1186/s40303-016-0018-8 · Cited by 41
Hong, I., Kang, T., Yoo, Y., Park, R., Lee, J., Lee, S., Kim, J., Song, B., Kim, S.-Y., Moon, M., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130311 · Cited by 41
“The 4 allele of the apolipoprotein E (APOE) gene has been iden-tified as the major risk factor for the more common late-onset AD [13].”
An apolipoprotein E4 fragment can promote intracellular accumulation of amyloid peptide beta 42
Dafnis, I., Stratikos, E., Tzinia, A., Tsilibary, E. C., Zannis, V. I., & Chroni, A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06756.x · Cited by 41
“Being homozygous or heterozygous for the ε4 allele increases the risk of AD four-fold and lowers the age of onset of late-onset AD (Corder et al. 1993; Myers et al. 1996).”
BackgroundInfluentialKazemeini, S., Nadeem-Tariq, A., Shih, R., Rafanan, J., Ghani, N., & Vida, T. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111720 · Cited by 41
“Early genetic testing, such as screening for APOE ε 4 status, could also be valuable in stratifying patient risk and guiding early interventions [239].”
BackgroundLipoprotein receptors in Alzheimer's disease
Andersen, O. M., & Willnow, T. E. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.09.002 · Cited by 41
Neuronal ApoE4 in Alzheimer’s disease and potential therapeutic targets
Zhang, L., Xia, Y., & Gui, Y. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1199434 · Cited by 41
“Epidemiological and genome-wide association studies have implicated ApoE4 as the largest genetic risk factor for late-onset AD (Corder et al., 1993; Shi et al., 2012).”
BackgroundmicroRNA-132 regulates gene expression programs involved in microglial homeostasis
Walgrave, H., Penning, A., Tosoni, G., Snoeck, S., Davie, K., Davis, E., Wolfs, L., Sierksma, A., Mars, M., Bu, T., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106829 · Cited by 41
Yamauchi, K., Tozuka, M., Hidaka, H., Hidaka, E., Kondo, Y., & Katsuyama, T. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.9.1431 · Cited by 41
Early-life stress leads to impaired spatial learning and memory in middle-aged ApoE4-TR mice
Lin, L.-Y., Zhang, J., Dai, X.-M., Xiao, N.-A., Wu, X.-L., Wei, Z., Fang, W.-T., Zhu, Y.-G., & Chen, X.-C. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0107-2 · Cited by 41
Albrecht, D. S., Sagare, A., Pachicano, M., Sweeney, M. D., Toga, A., Zlokovic, B., Chui, H., Joe, E., Schneider, L., Morris, J. C., et al. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2021.01.010 · Cited by 37
Cavedo, E., Lista, S., Rojkova, K., Chiesa, P. A., Houot, M., Brueggen, K., Blautzik, J., Bokde, A. L. W., Dubois, B., Barkhof, F., et al. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.05.048 · Cited by 40
“At present, the ε4 allelic variant of APOE – APOE ε4 – is the best established genetic risk factor for the development of late-onset Alzheimer’s Disease (AD) (Corder et al., 1993, Strittmatter et al., 1993).”
BackgroundHobel, Z., ageing, F. T. A. D. N. I. A. T. A. I. B. A. L. F. S. O., Isenberg, A. L., Raghupathy, D., Mack, W., & Pa, J. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180859 · Cited by 40
“Specifically, it has been reported in a number of studies that one copy of the 4 allele is sufficient to increase AD risk in women, whereas two copies but not one, increase risk in men [5, 7, 9, 38, 39].”
BackgroundDickson, T. C., Saunders, H. L., & Vickers, J. C. (1997) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1997.tb01325.x · Cited by 40
Kamboh, M. I., Aston, C. E., Perez-Tur, J., Kokmen, E., Ferrell, R. E., Hardy, J., & DeKosky, S. T. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00129-9 · Cited by 40
Henningfield, C. M., Arreola, M. A., Soni, N., Spangenberg, E. E., & Green, K. N. (2022) · Glia · doi:10.1002/glia.24105 · Cited by 40
“APOE*ε4 carriers have an increased risk to develop AD (Corder et al., 1993; Saunders et al., 1993) while APOE*ε2 carriers have a decreased risk (Corder et al., 1994; Farrer et al., 1997; Reiman et al., 2020).”
BackgroundMulder, M., & Terwel, D. (1998) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000022429 · Cited by 40
A novel variant apolipoprotein E Okayama in a patient with lipoprotein glomerulopathy
Kinomura, M., Sugiyama, H., Saito, T., Matsunaga, A., Sada, K.-E., Kanzaki, M., Takazawa, Y., Maeshima, Y., Yanai, H., & Makino, H. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm675 · Cited by 40
“ApoE4 may be a risk factor for atherosclerosis and Alzheimer’s disease [ 6 ].”
BackgroundBraak, H., & Del Tredici, K. (2020) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlz123 · Cited by 40
Associations of Alzheimer Disease–Protective APOE Variants With Age-Related Macular Degeneration
Rasmussen, K. L., Tybjærg-Hansen, A., Nordestgaard, B. G., & Frikke-Schmidt, R. (2023) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2022.4602 · Cited by 40
Bennett, R. E., Esparza, T. J., Lewis, H. A., Kim, E., Mac Donald, C. L., Sullivan, P. M., & Brody, D. L. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31828e24ab · Cited by 40
“(AD) (9, 10); 2) TBI is a major environmental risk factor”
Anti-amyloidogenic effect of Allium sativum in Alzheimer’s transgenic model Tg2576
Chauhan, N. B. (2003) · Journal of Herbal Pharmacotherapy · doi:10.1080/j157v03n01_05 · Cited by 39
Human iPSC application in Alzheimer’s disease and tau-related neurodegenerative diseases
TCW, J. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.01.043 · Cited by 39
Chan, E. S., Shetty, M. S., Sajikumar, S., Chen, C., Soong, T. W., & Wong, B.-S. (2016) · Scientific Reports · doi:10.1038/srep26119 · Cited by 39
Human apolipoprotein C-I expression in mice impairs learning and memory functions
Abildayeva, K., Berbée, J. F. P., Blokland, A., Jansen, P. J., Hoek, F. J., Meijer, O., Lütjohann, D., Gautier, T., Pillot, T., De Vente, J., et al. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m700518-jlr200 · Cited by 39
“The fibril formation of Ab(1-40) peptide was measured by a thioflavin-T binding assay as described previously (41, 42).”
BackgroundMethodInfluentialChallenge accepted: uncovering the role of rare genetic variants in Alzheimer’s disease
Khani, M., Gibbons, E., Bras, J., & Guerreiro, R. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00505-9 · Cited by 39
“These are referred to as APOE ε 2, ε 3 and ε 4, with APOE ε 3 being the most common among human populations, and ε 4 and ε 2 increasing and decreasing the risk for AD, respectively, in a dose-dependent manner [12, 13].”
BackgroundBorràs, C., Mercer, A., Sirisi, S., Alcolea, D., Escolà-Gil, J. C., Blanco-Vaca, F., & Tondo, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169356 · Cited by 39
“In contrast, the relatively rare ApoE2 is considered neuroprotective [29,115], whereas ApoE4 is considered the strongest genetic risk factor for sporadic late-onset AD [97,116,117].”
BackgroundHoulden, H., Crook, R., Hardy, J., Roques, P., Collinge, J., & Rossor, M. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90026-4 · Cited by 38
Asaro, A., Carlo‐Spiewok, A., Malik, A. R., Rothe, M., Schipke, C. G., Peters, O., Heeren, J., & Willnow, T. E. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12121 · Cited by 38
“[2] Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al.”
BackgroundPandey, R. S., Graham, L., Uyar, A., Preuss, C., Howell, G. R., & Carter, G. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0351-3 · Cited by 37
“Before the era of 84 large-scale genome wide association studies, the e4 allele of the apolipoprotein 85 E (APOE) gene was the only well-established major risk factor for LOAD, accounting for 86 about 30% of genetic variance [10, 11].”
BackgroundGeorgiadou, D., Stamatakis, K., Efthimiadou, E. K., Kordas, G., Gantz, D., Chroni, A., & Stratikos, E. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m030965 · Cited by 37
The presence of apoE4, not the absence of apoE3, contributes to AD pathology
Teter, B., Raber, J., Nathan, B., & Crutcher, K. A. (2002) · Journal of Alzheimer's Disease · doi:10.3233/jad-2002-4305 · Cited by 37
“ApoE4 increases the risk of cognitive impairments and of developing AD [16,17,20,74,98].”
Lim, W. L. F., Lam, S. M., Shui, G., Mondal, A., Ong, D., Duan, X., Creegan, R., Martins, I. J., Sharman, M. J., Taddei, K., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.03.012 · Cited by 37
“There is also a geneedosage effect, such that individuals with two copies of APOE ε4 alleles have the earliest age of onset (Corder et al., 1993; Poirier and Davignon, 1993).”
BackgroundAlzheimer’s disease: diagnostics, prognostics and the road to prevention
Grossman, I., Lutz, M. W., Crenshaw, D. G., Saunders, A. M., Burns, D. K., & Roses, A. D. (2010) · EPMA Journal · doi:10.1007/s13167-010-0024-3 · Cited by 37
“Conversely, the rare E2 allele has been associated with protection against LOAD compared with both the E4 allele and the more common E3 allele [21].”
Self-citationAguilar, C., Muehlboeck, J.-S., Mecocci, P., Vellas, B., Tsolaki, M., Kloszewska, I., Soininen, H., Lovestone, S., Wahlund, L.-O., Simmons, A., et al. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00145 · Cited by 34
The association between white matter hyperintensities and amyloid and tau deposition
Alban, S. L., Lynch, K. M., Ringman, J. M., Toga, A. W., Chui, H. C., Sepehrband, F., & Choupan, J. (2023) · NeuroImage: Clinical · doi:10.1016/j.nicl.2023.103383 · Cited by 35
“Homozygous APOE-ε 4 genotype is the genetic marker that significantly increases one ’ s risk for AD (Corder et al., 1993).”
Sun, G. G., Wang, C., Mazzarino, R. C., Perez-Corredor, P. A., Davtyan, H., Blurton-Jones, M., Lopera, F., Arboleda-Velasquez, J. F., & Shi, Y. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114982 · Cited by 36
LaDu, M. J., Stine, Narita, M., Getz, G. S., Reardon, C. A., & Bu, G. (2006) · Biochemistry · doi:10.1021/bi051765s · Cited by 36
Amyloid β in hereditary cerebral hemorrhage with amyloidosis-Dutch type
Kamp, J. A., Moursel, L. G., Haan, J., Terwindt, G. M., Lesnik Oberstein, S. A. M. J., van Duinen, S. G., & van Roon-Mom, W. M. C. (2014) · Reviews in the Neurosciences · doi:10.1515/revneuro-2014-0008 · Cited by 36
“ApoE is known to be the major risk factor for AD, and carrying one or two ε4 alleles is associated with a dose-dependent increase in AD risk (Corder et al., 1993).”
BackgroundQUINN, C. M., KÅGEDAL, K., TERMAN, A., STROIKIN, U., BRUNK, U. T., JESSUP, W., & GARNER, B. (2004) · Biochemical Journal · doi:10.1042/bj20031352 · Cited by 36
Zhang, W., Hu, C., Yang, Z., Zhou, Q., Peng, D., Yuan, X., Lv, Z., Pang, S., Jiang, W., Yang, C., et al. (2014) · Neural Regeneration Research · doi:10.4103/1673-5374.130117 · Cited by 36
“…age at clinical onset were 91% and 68 years in ε4 homozygotes, 47% and 76 years in heterozygotes, and 20% and 84 years in non-carriers, indicating that APOE ε4 increases the risk of developing Alzheimer’s disease at an earlier age of onset, in a gene dose dependent manner (Corder et al., 1993).”
BackgroundRole of Microglia in Regulating Cholesterol and Tau Pathology in Alzheimer’s Disease
Nanjundaiah, S., Chidambaram, H., Chandrashekar, M., & Chinnathambi, S. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00883-6 · Cited by 36
A Multi-Center Study of ACE and the Risk of Late-Onset Alzheimer's Disease
Belbin, O., Brown, K., Shi, H., Medway, C., Abraham, R., Passmore, P., Mann, D., Smith, A. D., Holmes, C., McGuinness, B., et al. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-101914 · Cited by 34
“LOAD since its first report as a candidate gene almost 20 years ago [13, 14].”
BackgroundLlano, D. A., Devanarayan, P., & Devanarayan, V. (2019) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000328 · Cited by 35
H. Swerdlow, R. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211798072535 · Cited by 35
“2 region [101].”
Genetic resilience to Alzheimer's disease in APOE ε4 homozygotes: A systematic review
Huq, A. J., Fransquet, P., Laws, S. M., Ryan, J., Sebra, R., Masters, C. L., Winship, I. M., James, P. A., & Lacaze, P. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.05.011 · Cited by 35
APOE epsilon-4 allele and cytokine production in Alzheimer's disease
Olgiati, P., Politis, A., Malitas, P., Albani, D., Dusi, S., Polito, L., De Mauro, S., Zisaki, A., Piperi, C., Stamouli, E., et al. (2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2344 · Cited by 35
“A significant association between the epsilon 4 allele of the APOE gene (APOE4) and AD has been consistently demonstrated since 1993 (Corder et al., 1993; Saunders et al., 1993; Strittmatter et al., 1993).”
BackgroundHippocampus-related cognitive impairments in young apoE4 targeted replacement mice
Salomon-Zimri, S., Boehm-Cagan, A., Liraz, O., & Michaelson, D. M. (2013) · Neurodegenerative Diseases · doi:10.1159/000354777 · Cited by 34
Hurtado, M. O., Kohler, I., & de Lange, E. C. M. (2018) · Bioanalysis · doi:10.4155/bio-2018-0135 · Cited by 34
O'Dwyer, L., Lamberton, F., Matura, S., Scheibe, M., Miller, J., Rujescu, D., Prvulovic, D., & Hampel, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036024 · Cited by 34
Guest, F. L., Rahmoune, H., & Guest, P. C. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-42667-5_8 · Cited by 34
Isoform-specific effects of apoE on neurite outgrowth in olfactory epithelium culture
Hussain, A., Luong, M., Pooley, A., & Nathan, B. P. (2013) · Journal of Biomedical Science · doi:10.1186/1423-0127-20-49 · Cited by 34
“Numerous genetic studies have revealed that inheritance of apoE4 allele increases the risk and rate of progression of late-onset Alzheimer disease [5-9].”
Bracher-Smith, M., Leonenko, G., Baker, E., Crawford, K., Graham, A. C., Salih, D. A., Howell, B. W., Hardy, J., & Escott-Price, V. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.07.009 · Cited by 31
Remer, J., Dean, D. C., Chen, K., Reiman, R. A., Huentelman, M. J., Reiman, E. M., & Deoni, S. C. L. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117243 · Cited by 33
Kloske, C. M., Belloy, M. E., Blue, E. E., Bowman, G. R., Carrillo, M. C., Chen, X., Chiba‐Falek, O., Davis, A. A., Paolo, G. D., Garretti, F., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13877 · Cited by 33
APOE2 mitigates disease-related phenotypes in an isogenic hiPSC-based model of Alzheimer’s disease
Brookhouser, N., Raman, S., Frisch, C., Srinivasan, G., & Brafman, D. A. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01076-3 · Cited by 33
“greatly reducing the mean age of onset [7].”
BackgroundChen, Y.-Y., Wang, M.-C., Wang, Y.-N., Hu, H.-H., Liu, Q.-Q., Liu, H.-J., & Zhao, Y.-Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-00218-z · Cited by 33
“There are three major APOE alleles in humans, among which APOE2 allele is closely associated with the reduced risk of AD, while APOE4 allele devotes much to AD occurrence [22].”
BackgroundFunctional interaction between APOE4 and LDL receptor isoforms in Alzheimer's disease
Cheng, D., Huang, R., Lanham, I. S., Cathcart, H. M., Howard, M., Corder, E. H., & Poduslo, S. E. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2004.024968 · Cited by 33
Self-citationComplement receptor 1 gene (CR1) intragenic duplication and risk of Alzheimer’s disease
ARUK Consortium, Kucukkilic, E., Brookes, K., Barber, I., Guetta-Baranes, T., Morgan, K., & Hollox, E. J. (2018) · Human Genetics · doi:10.1007/s00439-018-1883-2 · Cited by 33
Metadata
- Authors
- Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A.
- Affiliations
- Duke University (US)
- Duke Medical Center (US)
- University of California, Los Angeles (US)
- Massachusetts General Hospital (US)
- Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University Medical Center, Durham, NC 27710.
- Venue
- Science
- Published
- 1993-08-13
- Volume
- 261
- Issue
- 5123
- Pages
- 921-923
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2036362108
- Cited by
- 9,429
- References
- 16
- Citations by year
- 2026: 289 · 2025: 380 · 2024: 355 · 2023: 328 · 2022: 356 · 2021: 378 · 2020: 396 · 2019: 358 · 2018: 341 · 2017: 343 · 2016: 345 · 2015: 303 · 2014: 343 · 2013: 335 · 2012: 333
- FWCI
- 135.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, gene dosage, Alzheimer's disease, genetic risk, homozygosity, age of onset, genetic association
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alleles, Alzheimer Disease, Apolipoproteins E, Female, Gene Frequency, Genotype, Homozygote, Humans, Male, Risk Factors, Linkage Disequilibrium, Survival Rate, Amyloid beta-Peptides, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.